SolFocus Showcases New Concentrator Photovoltaic (CPV) Technology and Commercial Deployment Success at CPV Summit 2009 in Toledo, Spain
SolFocus Showcases New Concentrator Photovoltaic (CPV) Technology and Commercial Deployment Success at CPV Summit 2009 in Toledo, Spain
SolFocus, Inc., a leading developer and supplier of Concentrator Photovoltaic (CPV) systems, announced today that it will be showcasing its new CPV technology at the CPV Summit 2009 in Toledo, Spain, April 28-29. This will be the first time that this new technology – the SF-1100S – will be shown in Europe. The SF-1100S is the CPV technology which SolFocus will be installing in Greece as part of its 10MW project with Samaras Group. Installation of the systems will begin this summer. The company also expects to be installing in other European countries including Italy and Portugal before the end of the year.
At the conference on April 28th SolFocus will be sharing with the conference attendees its ISFOC experience. SolFocus was part of the first phase of the ISFOC project, and was the first company to complete its installations. The company has a total of .5MW installed at ISFOC. “We are extremely pleased with the performance of our systems,” commented SolFocus Europe President Roberto de Diego. “Of particular importance with new technology is consistency. Our systems have performed at or above rated levels consistently over the nine months since installation.”
SolFocus founder and Chairman Gary D. Conley will also be participating in the conference on April 29th , chairing the session on New Markets for CPV. Mr. Conley was an early visionary for commercialization of the industry with his research into CPV approaches which would allow high volume, low cost manufacturing. This research led to the founding of SolFocus in late 2006. Mr. Conley was also instrumental in the formation of the CPV Consortium, an industry organization dedicated to the advancement of the CPV industry. The CPV Consortium will be having an information meeting at the conference for new members who want to be engaged in directing the evolution of and infrastructure for the industry.
SolFocus is a sponsor of the conference.
About SolFocus
The SolFocus mission is to enable solar energy generation at a Levelized Cost of Energy (LCOE) competitive with traditional fossil fuel sources. To achieve this goal, SolFocus has developed leading concentrator photovoltaic (CPV) technology which combines high-efficiency solar cells (approaching 40 percent) and advanced optics to provide solar energy solutions which are scalable, dependable and capable of delivering on the promise of clean, low-cost, renewable energy. SolFocus is headquartered in Mountain View, Calif., with European operations headquartered in Madrid, Spain, and manufacturing in Mesa, Ariz., as well as manufacturing partners in India and China.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact:
SPAIN:
SolFocus Europe
Roberto de Diego Arozamena, +34 911 77
39 01
President
roberto_deDiego@solfocus.com
or
A&R
Edelman
Veronica Barranco, +34 91 556 01 54
veronica.barranco@edelman.com
or
US:
SolFocus
Nancy
Hartsoch, 460-623-7134
VP Marketing
Mobile: 408-209-9250
Nancy_hartsoch@solfocus.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom